135 related articles for article (PubMed ID: 19450079)
1. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Postma MJ; Beardsworth P; Wilschut JC
J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
[TBL] [Abstract][Full Text] [Related]
2. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE; Brogan AJ; Winiarski AP
Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
[TBL] [Abstract][Full Text] [Related]
3. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
4. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Fisher D; Kelly B; Rose DN
Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
Muennig PA; Khan K
Clin Infect Dis; 2001 Dec; 33(11):1879-85. PubMed ID: 11692300
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
Orzeck EA; Shi N; Blumentals WA
Clin Ther; 2007 Oct; 29(10):2246-55. PubMed ID: 18042482
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
[TBL] [Abstract][Full Text] [Related]
8. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
[TBL] [Abstract][Full Text] [Related]
9. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study.
Blumentals WA; Schulman KL
Curr Med Res Opin; 2007 Dec; 23(12):2961-70. PubMed ID: 17939881
[TBL] [Abstract][Full Text] [Related]
10. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Talbird SE; Brogan AJ; Winiarski AP; Sander B
Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
[TBL] [Abstract][Full Text] [Related]
12. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Shen K; Xiong T; Tan SC; Wu J
PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
[TBL] [Abstract][Full Text] [Related]
13. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
Lugnér AK; Mylius SD; Wallinga J
Health Econ; 2010 May; 19(5):518-31. PubMed ID: 19382106
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Kashiwagi S
J Infect; 2009 Sep; 59(3):207-12. PubMed ID: 19619898
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness analysis of oseltamivir phosphorus in the treatment of influenza].
Hu SL; Lin JT; Yu XZ; Wang AX; Zhu JH; Cui DJ; Chen XY; Wang YZ; Wu XD; Gao H
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1664-7. PubMed ID: 15569469
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan.
Nagase H; Moriwaki K; Kamae M; Yanagisawa S; Kamae I
Value Health; 2009; 12 Suppl 3():S62-5. PubMed ID: 20586984
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.
Vindt Holm M; Gyldmark M; Holme Hansen E
Pharm World Sci; 2004 Dec; 26(6):339-45. PubMed ID: 15683104
[TBL] [Abstract][Full Text] [Related]
19. Use of oseltamivir in Dutch nursing homes during the 2004-2005 influenza season.
van der Sande MA; Ruijs WL; Meijer A; Cools HJ; van der Plas SM
Vaccine; 2006 Nov; 24(44-46):6664-9. PubMed ID: 16797806
[TBL] [Abstract][Full Text] [Related]
20. Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan.
Chang YM; Li WC; Huang CT; Huang CG; Tsao KC; Cheng YH; Chiang SL; Yang SY; Chen CH; Huang YC
J Hosp Infect; 2008 Jan; 68(1):83-7. PubMed ID: 17945389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
